1458 related articles for article (PubMed ID: 17387718)
1. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
[TBL] [Abstract][Full Text] [Related]
2. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
[TBL] [Abstract][Full Text] [Related]
3. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
John EM; Koo J; Phipps AI; Longacre TA; Kurian AW; Ingles SA; Wu AH; Hines LM
Breast Cancer Res; 2024 May; 26(1):88. PubMed ID: 38822357
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of breast cancer subtypes and survival among Hispanic women with invasive breast cancer in California.
Banegas MP; Tao L; Altekruse S; Anderson WF; John EM; Clarke CA; Gomez SL
Breast Cancer Res Treat; 2014 Apr; 144(3):625-34. PubMed ID: 24658879
[TBL] [Abstract][Full Text] [Related]
5. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancers are increased in black women regardless of age or body mass index.
Stead LA; Lash TL; Sobieraj JE; Chi DD; Westrup JL; Charlot M; Blanchard RA; Lee JC; King TC; Rosenberg CL
Breast Cancer Res; 2009; 11(2):R18. PubMed ID: 19320967
[TBL] [Abstract][Full Text] [Related]
8. The joint contribution of tumor phenotype and education to breast cancer survival disparity between Hispanic and non-Hispanic white women.
Boone SD; Baumgartner KB; Joste NE; Pinkston CM; Yang D; Baumgartner RN
Cancer Causes Control; 2014 Mar; 25(3):273-82. PubMed ID: 24337810
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of breast cancer subtypes in adolescent and young adult women.
Keegan TH; DeRouen MC; Press DJ; Kurian AW; Clarke CA
Breast Cancer Res; 2012 Mar; 14(2):R55. PubMed ID: 22452927
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
[TBL] [Abstract][Full Text] [Related]
11. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
[TBL] [Abstract][Full Text] [Related]
12. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014.
Scott LC; Mobley LR; Kuo TM; Il'yasova D
Cancer; 2019 Oct; 125(19):3412-3417. PubMed ID: 31282032
[TBL] [Abstract][Full Text] [Related]
13. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
14. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry.
Telli ML; Chang ET; Kurian AW; Keegan TH; McClure LA; Lichtensztajn D; Ford JM; Gomez SL
Breast Cancer Res Treat; 2011 Jun; 127(2):471-8. PubMed ID: 20957431
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
16. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
[TBL] [Abstract][Full Text] [Related]
17. Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis.
John EM; McGuire V; Kurian AW; Koo J; Shariff-Marco S; Gomez SL; Cheng I; Keegan THM; Kwan ML; Bernstein L; Vigen C; Wu AH
Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):351-363. PubMed ID: 33355191
[TBL] [Abstract][Full Text] [Related]
18. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.
Parise CA; Caggiano V
Cancer Causes Control; 2019 May; 30(5):417-424. PubMed ID: 30879205
[TBL] [Abstract][Full Text] [Related]
19. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.
Keegan TH; Press DJ; Tao L; DeRouen MC; Kurian AW; Clarke CA; Gomez SL
Breast Cancer Res; 2013; 15(5):R95. PubMed ID: 24131591
[TBL] [Abstract][Full Text] [Related]
20. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.
Kohler BA; Sherman RL; Howlader N; Jemal A; Ryerson AB; Henry KA; Boscoe FP; Cronin KA; Lake A; Noone AM; Henley SJ; Eheman CR; Anderson RN; Penberthy L
J Natl Cancer Inst; 2015 Jun; 107(6):djv048. PubMed ID: 25825511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]